Postdoctoral Fellow of Medical Ethics
NYU Grossman School of Medicine, New York
Alen Agaronov ScD is a Postdoctoral Fellow in the Division of Medical Ethics at NYU Grossman School of Medicine, where he focuses on the tension between industry innovation, evidence generation, and patient access to new medical technologies. His practice operates between public science, STS, program evaluation, critical media, and bioethics.
His recent work has touched on "real-world" evidence generation from investigational medical products offered outside of clinical trials (a practice known as "expanded access"). Notable cases include convalescent plasma for COVID-19 and tecovirimat for mpox. His current work is focused on the role of patient advocacy in regulatory and payer decision-making for novel therapies for unmet needs, including Amylyx's Relyvrio (AMX0035) for amyotrophic lateral sclerosis (ALS) and Sarepta’s Elevidys (SRP-9001) for Duchenne muscular dystrophy.
He is a member of the Division of Medical Ethics' interdisciplinary working groups on Compassionate Use and Pre-Approval Access (CUPA), Ethics & Real-World Evidence (ERWE), and Pediatric Gene Therapy & Medical Ethics (PGTME).
Dr. Agaronov received a doctoral degree in Social & Behavioral Sciences from the Harvard T.H. Chan School of Public Health, where he also pursued a secondary field in Critical Media Practice through The Film Study Center at Harvard University, and where he was a regular teaching fellow and curriculum designer for courses on aesthetics, engineering, politics, social medicine, demography, and higher education at Harvard College. For his dissertation Dr. Agaronov evaluated the implementation of public health initiatives in partnership with Levi Strauss & Co. apparel manufacturers in Mexico and Head Start child care centers in Boston. Some of his previous research also focused on the oral history of cardiovascular disease epidemiology. He received a BS-MS from CUNY Hunter College.
Disclosure(s): No financial relationships to disclose
Revisiting Convalescent Plasma – Again: Ethical Stewardship of Immunology’s “Holy Grail”
Thursday, October 12, 2023
8:15 AM – 9:30 AM ET
Saturday, October 14, 2023
10:30 AM – 11:45 AM ET